These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6111584)

  • 1. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.
    Toru M; Matsuda O; Makiguchi K; Sugano K
    J Nerv Ment Dis; 1981 May; 169(5):324-7. PubMed ID: 6111584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
    Kuno S; Mizuta E; Yamasaki S
    Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome after neuroleptic discontinuation.
    Amore M; Zazzeri N
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1323-34. PubMed ID: 8868212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complications of drug withdrawal from antiparkinson agents and neuroleptics].
    Mizon JP; Rosa A
    Therapie; 1984; 39(4):421-5. PubMed ID: 6148792
    [No Abstract]   [Full Text] [Related]  

  • 6. Malignant syndrome in Parkinson's disease: concept and review of the literature.
    Mizuno Y; Takubo H; Mizuta E; Kuno S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S3-9. PubMed ID: 12735909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study.
    Horiguchi J; Nishimatsu O
    Jpn J Psychiatry Neurol; 1992 Sep; 46(3):733-9. PubMed ID: 1362592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication.
    Stotz M; Thümmler D; Schürch M; Renggli JC; Urwyler A; Pargger H
    Br J Anaesth; 2004 Dec; 93(6):868-71. PubMed ID: 15377584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report.
    Fiore S; Persichino L; Anticoli S; De Pandis MF
    Acta Biomed; 2014 Dec; 85(3):281-4. PubMed ID: 25567468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
    Keyser DL; Rodnitzky RL
    Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of impending neuroleptic malignant syndrome associated with Shy-Drager syndrome].
    Kumagai R; Harada T; Kurokawa K; Okazaki M; Egi N; Shimote K; Nakamura S
    No To Shinkei; 1998 Aug; 50(8):745-9. PubMed ID: 9757468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders.
    Takubo H; Harada T; Hashimoto T; Inaba Y; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S31-41. PubMed ID: 12735913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms.
    Bezchlibnyk-Butler KZ; Remington GJ
    Can J Psychiatry; 1994 Mar; 39(2):74-84. PubMed ID: 7908605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The abrupt withdrawal of antiparkinsonian drugs in mentally handicapped patients.
    Carter G
    Br J Psychiatry; 1983 Feb; 142():166-8. PubMed ID: 6132644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?
    Henderson VW; Wooten GF
    Neurology; 1981 Feb; 31(2):132-7. PubMed ID: 6110195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Late extrapyramidal hyperkinesis and neuroleptic withdrawal dyskinesia. Practical problems].
    Hoffmann C; Faust V
    Fortschr Med; 1983 Mar; 101(11):470-6. PubMed ID: 6133824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease.
    Douglas A; Morris J
    Age Ageing; 2006 Nov; 35(6):640-1. PubMed ID: 16943262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs.
    Luchins DJ; Freed WJ; Wyatt RJ
    Am J Psychiatry; 1980 Nov; 137(11):1395-8. PubMed ID: 6108078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rhabdomyolysis as a complication of Parkinson's disease].
    Pozzoni P; Tentori F; Corti M; Pozzi C
    G Ital Nefrol; 2002; 19(1):13-7. PubMed ID: 12165940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group.
    Ikebe S; Harada T; Hashimoto T; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Takubo H; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S47-9. PubMed ID: 12735915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.